Favorable effects of glycolate conjugation on the biodistribution of humanized antiTac Fab fragment

Hisataka Kobayashi, Kim In-Sook, Debbie Drumm, Meyoung-Kon Kim, David S. Paik, Nhat Le, Thomas A. Waldmann, Jorge A. Carrasquillo, Chang H. Paik

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

One of the major limitations of using intact immunoglobulins for targeting tumors is poor penetration into tissues. Although Fab fragments have been used because of their improved kinetics, they have undesirable high renal accumulation. In this study we tested a new approach to block renal accumulation of Fab. Methods: We conjugated humanized antiTac Fab fragments, which are directed against the interleukin-2 receptor, with glycolate. The biodistribution, pharmacokinetics and catabolism of glycolated Fab (glyco- Fab) were evaluated at two different levels of substitution (heavy and light) compared with nonglycolated Fab in Tac-antigen-positive (ATAC4) and -negative (A431) tumor-bearing nude mice. The mice received coinjections of 125I- labeled glyco-Fab (3 μCi/1 μg) and 131I-labeled nonglycolated Fab (5 μCi/1 μg). In addition, groups of mice receiving these reagents were also coinfused with 50 mg L-lysine. Results: Significantly less glyco-Fab than nonglycolated Fab accumulated in the kidney (21 versus 189 %ID/g; P < 0.001). A higher proportion of glyco-Fab was excreted into the urine in its intact form. The glyco-Fab survived longer in circulation than nonglycolated Fab. The peak tumor accumulation of glyco-Fab was 2.3-fold greater than that of nonglycolated Fab. Furthermore, the ATAC4 tumor-to-normal tissue ratio of glyco-Fab was much higher in all organs than that of nonglycolated Fab. The heavily glyco-Fab accumulated less in the kidney than the lightly glyco-Fab. The coinjected lysine reduced the renal accumulation of both nonglycolated Fab and glyco-Fab. Conclusion: Glyco-Fab is a promising agent because of its lower renal accumulation, higher tumor uptake and higher tumor-to-normal tissue ratio.

Original languageEnglish
Pages (from-to)837-845
Number of pages9
JournalJournal of Nuclear Medicine
Volume40
Issue number5
Publication statusPublished - 1999 May 1
Externally publishedYes

Fingerprint

glycolic acid
Immunoglobulin Fab Fragments
Kidney
Neoplasms
Lysine
Interleukin-2 Receptors
Nude Mice
Immunoglobulins
Pharmacokinetics
Urine

Keywords

  • Fab fragment
  • Glycolate
  • Monoclonal antibody
  • Radioimmunodetection

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Kobayashi, H., In-Sook, K., Drumm, D., Kim, M-K., Paik, D. S., Le, N., ... Paik, C. H. (1999). Favorable effects of glycolate conjugation on the biodistribution of humanized antiTac Fab fragment. Journal of Nuclear Medicine, 40(5), 837-845.

Favorable effects of glycolate conjugation on the biodistribution of humanized antiTac Fab fragment. / Kobayashi, Hisataka; In-Sook, Kim; Drumm, Debbie; Kim, Meyoung-Kon; Paik, David S.; Le, Nhat; Waldmann, Thomas A.; Carrasquillo, Jorge A.; Paik, Chang H.

In: Journal of Nuclear Medicine, Vol. 40, No. 5, 01.05.1999, p. 837-845.

Research output: Contribution to journalArticle

Kobayashi, H, In-Sook, K, Drumm, D, Kim, M-K, Paik, DS, Le, N, Waldmann, TA, Carrasquillo, JA & Paik, CH 1999, 'Favorable effects of glycolate conjugation on the biodistribution of humanized antiTac Fab fragment', Journal of Nuclear Medicine, vol. 40, no. 5, pp. 837-845.
Kobayashi, Hisataka ; In-Sook, Kim ; Drumm, Debbie ; Kim, Meyoung-Kon ; Paik, David S. ; Le, Nhat ; Waldmann, Thomas A. ; Carrasquillo, Jorge A. ; Paik, Chang H. / Favorable effects of glycolate conjugation on the biodistribution of humanized antiTac Fab fragment. In: Journal of Nuclear Medicine. 1999 ; Vol. 40, No. 5. pp. 837-845.
@article{9f3ceb6845124bd09cdf159339620fbf,
title = "Favorable effects of glycolate conjugation on the biodistribution of humanized antiTac Fab fragment",
abstract = "One of the major limitations of using intact immunoglobulins for targeting tumors is poor penetration into tissues. Although Fab fragments have been used because of their improved kinetics, they have undesirable high renal accumulation. In this study we tested a new approach to block renal accumulation of Fab. Methods: We conjugated humanized antiTac Fab fragments, which are directed against the interleukin-2 receptor, with glycolate. The biodistribution, pharmacokinetics and catabolism of glycolated Fab (glyco- Fab) were evaluated at two different levels of substitution (heavy and light) compared with nonglycolated Fab in Tac-antigen-positive (ATAC4) and -negative (A431) tumor-bearing nude mice. The mice received coinjections of 125I- labeled glyco-Fab (3 μCi/1 μg) and 131I-labeled nonglycolated Fab (5 μCi/1 μg). In addition, groups of mice receiving these reagents were also coinfused with 50 mg L-lysine. Results: Significantly less glyco-Fab than nonglycolated Fab accumulated in the kidney (21 versus 189 {\%}ID/g; P < 0.001). A higher proportion of glyco-Fab was excreted into the urine in its intact form. The glyco-Fab survived longer in circulation than nonglycolated Fab. The peak tumor accumulation of glyco-Fab was 2.3-fold greater than that of nonglycolated Fab. Furthermore, the ATAC4 tumor-to-normal tissue ratio of glyco-Fab was much higher in all organs than that of nonglycolated Fab. The heavily glyco-Fab accumulated less in the kidney than the lightly glyco-Fab. The coinjected lysine reduced the renal accumulation of both nonglycolated Fab and glyco-Fab. Conclusion: Glyco-Fab is a promising agent because of its lower renal accumulation, higher tumor uptake and higher tumor-to-normal tissue ratio.",
keywords = "Fab fragment, Glycolate, Monoclonal antibody, Radioimmunodetection",
author = "Hisataka Kobayashi and Kim In-Sook and Debbie Drumm and Meyoung-Kon Kim and Paik, {David S.} and Nhat Le and Waldmann, {Thomas A.} and Carrasquillo, {Jorge A.} and Paik, {Chang H.}",
year = "1999",
month = "5",
day = "1",
language = "English",
volume = "40",
pages = "837--845",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "5",

}

TY - JOUR

T1 - Favorable effects of glycolate conjugation on the biodistribution of humanized antiTac Fab fragment

AU - Kobayashi, Hisataka

AU - In-Sook, Kim

AU - Drumm, Debbie

AU - Kim, Meyoung-Kon

AU - Paik, David S.

AU - Le, Nhat

AU - Waldmann, Thomas A.

AU - Carrasquillo, Jorge A.

AU - Paik, Chang H.

PY - 1999/5/1

Y1 - 1999/5/1

N2 - One of the major limitations of using intact immunoglobulins for targeting tumors is poor penetration into tissues. Although Fab fragments have been used because of their improved kinetics, they have undesirable high renal accumulation. In this study we tested a new approach to block renal accumulation of Fab. Methods: We conjugated humanized antiTac Fab fragments, which are directed against the interleukin-2 receptor, with glycolate. The biodistribution, pharmacokinetics and catabolism of glycolated Fab (glyco- Fab) were evaluated at two different levels of substitution (heavy and light) compared with nonglycolated Fab in Tac-antigen-positive (ATAC4) and -negative (A431) tumor-bearing nude mice. The mice received coinjections of 125I- labeled glyco-Fab (3 μCi/1 μg) and 131I-labeled nonglycolated Fab (5 μCi/1 μg). In addition, groups of mice receiving these reagents were also coinfused with 50 mg L-lysine. Results: Significantly less glyco-Fab than nonglycolated Fab accumulated in the kidney (21 versus 189 %ID/g; P < 0.001). A higher proportion of glyco-Fab was excreted into the urine in its intact form. The glyco-Fab survived longer in circulation than nonglycolated Fab. The peak tumor accumulation of glyco-Fab was 2.3-fold greater than that of nonglycolated Fab. Furthermore, the ATAC4 tumor-to-normal tissue ratio of glyco-Fab was much higher in all organs than that of nonglycolated Fab. The heavily glyco-Fab accumulated less in the kidney than the lightly glyco-Fab. The coinjected lysine reduced the renal accumulation of both nonglycolated Fab and glyco-Fab. Conclusion: Glyco-Fab is a promising agent because of its lower renal accumulation, higher tumor uptake and higher tumor-to-normal tissue ratio.

AB - One of the major limitations of using intact immunoglobulins for targeting tumors is poor penetration into tissues. Although Fab fragments have been used because of their improved kinetics, they have undesirable high renal accumulation. In this study we tested a new approach to block renal accumulation of Fab. Methods: We conjugated humanized antiTac Fab fragments, which are directed against the interleukin-2 receptor, with glycolate. The biodistribution, pharmacokinetics and catabolism of glycolated Fab (glyco- Fab) were evaluated at two different levels of substitution (heavy and light) compared with nonglycolated Fab in Tac-antigen-positive (ATAC4) and -negative (A431) tumor-bearing nude mice. The mice received coinjections of 125I- labeled glyco-Fab (3 μCi/1 μg) and 131I-labeled nonglycolated Fab (5 μCi/1 μg). In addition, groups of mice receiving these reagents were also coinfused with 50 mg L-lysine. Results: Significantly less glyco-Fab than nonglycolated Fab accumulated in the kidney (21 versus 189 %ID/g; P < 0.001). A higher proportion of glyco-Fab was excreted into the urine in its intact form. The glyco-Fab survived longer in circulation than nonglycolated Fab. The peak tumor accumulation of glyco-Fab was 2.3-fold greater than that of nonglycolated Fab. Furthermore, the ATAC4 tumor-to-normal tissue ratio of glyco-Fab was much higher in all organs than that of nonglycolated Fab. The heavily glyco-Fab accumulated less in the kidney than the lightly glyco-Fab. The coinjected lysine reduced the renal accumulation of both nonglycolated Fab and glyco-Fab. Conclusion: Glyco-Fab is a promising agent because of its lower renal accumulation, higher tumor uptake and higher tumor-to-normal tissue ratio.

KW - Fab fragment

KW - Glycolate

KW - Monoclonal antibody

KW - Radioimmunodetection

UR - http://www.scopus.com/inward/record.url?scp=0345643317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0345643317&partnerID=8YFLogxK

M3 - Article

C2 - 10319759

AN - SCOPUS:0345643317

VL - 40

SP - 837

EP - 845

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 5

ER -